ストックスクリーナーアプリを入手
5.14
0.96%
-0.05
プレマーケット:
5.14
Immuneering Corp (IMRX) 最新ニュース
Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX) - TradingView
IMRX Forecast — Price Target — Prediction for 2027 - TradingView
Immuneering CEO Zeskind buys $10,948 in stock - Investing.com UK
Form 4 Immuneering Corp For: 24 June By Investing.com - Investing.com Canada
Immuneering CEO Zeskind buys $10,948 in stock By Investing.com - Investing.com Canada
Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading - Stock Titan
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant - Stock Titan
Immuneering names Andrew Gengos as CFO - MSN
Immuneering names Andrew Gengos as chief financial officer - Investing.com
Immuneering Appoints Andrew Gengos as Chief Financial Officer - The Manila Times
Immuneering names Andrew Gengos as chief financial officer By Investing.com - Investing.com Canada
IMRX begins dosing in phase III pancreatic cancer study, stock up - MSN
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026 - Minichart
Immuneering doses first patient in phase 3 pancreatic cancer trial - Investing.com
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - The Manila Times
Immuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
Uprising in pancreatic space more than Revolution - BioWorld News
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Mizuho reiterates Immuneering stock rating after trial data update - Investing.com
Immuneering Corporation 8-K SEC Filing: Company Information, NASDAQ Listing, and Compliance Details (June 1, 2026) - Minichart
According to a document submitted to the U.S. Securities and Exchange Commission, as of April 24, 2026, biotechnology company Immuneering Corp observed a median overall survival of 17.3 months in the intent-to-treat population of its 320 mg dosage gro - Bitget
[8-K] Immuneering Corp Reports Material Event - Stock Titan
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering stock maintained at Outperform by Oppenheimer on survival data - Investing.com South Africa
Immuneering reports median survival data from pancreatic trial - Investing.com
Immuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with Atebimetinib - Quiver Quantitative
Pancreatic cancer drug combo shows 17.3-month survival in trial - Stock Titan
Immuneering Corp stock (US45255L1089): IMRX trades around 5.36 USD ahead of key June data - AD HOC NEWS
IMRXImmuneering Corp Stock Price and Quote - Finviz
Immuneering Corporation (IMRX) Slides 2.2% as Pressure Mounts Near Key SupportBreakout Stock Alerts - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentCFO Commentary Report - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower Loss Exceeds Expectations as Pipeline Progress ContinuesPre-Announcement Alert - newsline.com
ASCO to spotlight pancreatic cancer innovation beyond KRAS - BioCentury
MEK inhibitor delivers 17.3-month OS for pancreatic cancer - BioWorld News
IMRX Jumps As Immuneering Touts Atebimetinib Pipeline Momentum - timothysykes.com
Immuneering reports 17.3-month survival in pancreatic cancer trial - Investing.com
Immuneering stock jumps on pancreatic cancer trial data By Investing.com - Investing.com Nigeria
Immuneering stock jumps on pancreatic cancer trial data - Investing.com
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy - The Manila Times
Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026 - Quiver Quantitative
Pancreatic cancer trial of Immuneering drug hits 17.3-month median survival - Stock Titan
Immuneering Corp stock (US45255L1089): clinical updates keep biotech investors watching - AD HOC NEWS
Immuneering Corporation (IMRX) Stock: Jumps +3.89%, Approaching $5.33 2026-05-20Diamond Pattern - The Legal Advocate
Can Revolution’s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes - BioSpace
Immuneering stock (US45255L1089): Insider buying puts the biotech back in focus - AD HOC NEWS
Immuneering Corporation Reports Q1 2026 Financial Results and Announces Positive Phase 2a Pancreatic Cancer Trial Data – Minichart - Minichart
0.05%
0.74%
大文字化:
|
ボリューム (24 時間):